SynBioVen Overview

SynBioVen, established in early 2022, focuses on supporting the next generation of synthetic biology scientists, founders, and startups. The firm believes that synthetic biology will drive the next industrial revolution and the transition to a net-zero economy, with UK companies playing a leading role. SynBioVen provides early-stage funding, including proof-of-concept, pre-seed, and seed investments, and offers access to expertise in synthetic biology research, business development, and financing. Additionally, portfolio companies benefit from support through SynbiCITE and access to the London Biofoundry.

Is SynBioVen the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with SynBioVen, along with a list of other relevant VCs, is available on Hopohopo.io.

SynBioVen

VC Fund

Investment focus

Invest in

Western Europe 1 / 14

Product type

Software
Software-enabled hardware
Materials
Drugs / Pharma

Industries / verticals

BioTech & Life Sciences

Investment role

Lead and follow

Stages

Pre-seed, Seed

First ticket size

£1,000,000 - £1,610,000

How to approach funds like SynBioVen

When reaching out to SynBioVen, founders should highlight how their technology leverages synthetic biology to address large-scale, real-world challenges, especially those with potential for global impact. Demonstrating a clear path from scientific innovation to commercial application, and articulating how access to specialized infrastructure or networks could accelerate development, will resonate. Emphasize your team's technical depth and your vision for scaling within the UK and beyond, as SynBioVen values founders who can bridge cutting-edge research with entrepreneurial execution.